Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    REGENXBIO Inc.

    NASDAQ: RGNX · Real-Time Price · USD
    9.14
    -0.13 (-1.40%)
    At close: Jun 16, 2025, 3:59 PM
    9.18
    0.44%
    Pre-market: Jun 17, 2025, 08:04 AM EDT

    REGENXBIO Statistics

    Share Statistics

    REGENXBIO has 50.16M shares outstanding. The number of shares has increased by 1.69% in one year.

    Shares Outstanding

    n/a
    		 50.16M

    Shares Change (YoY)

    n/a
    		 1.69%

    Shares Change (QoQ)

    n/a
    		 1.09%

    Owned by Institutions (%)

    n/a
    		 82.82%

    Shares Floating

    n/a
    		 45.45M

    Failed to Deliver (FTD) Shares

    n/a
    		 588

    FTD / Avg. Volume

    n/a
    		 0.05%

    Short Selling Information

    The latest short interest is 6.02M, so 12% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.02M

    Short % of Shares Out

    n/a
    		 12%

    Short % of Float

    n/a
    		 14.6%

    Short Ratio (days to cover)

    n/a
    		 5.62

    Valuation Ratios

    The PE ratio is -1.69 and the forward PE ratio is -6.14. REGENXBIO's PEG ratio is 0.07.

    PE Ratio

    n/a
    		 -1.69

    Forward PE

    n/a
    		 -6.14

    PS Ratio

    n/a
    		 4.59

    Forward PS

    n/a
    		 0.6

    PB Ratio

    n/a
    		 1.47

    P/FCF Ratio

    n/a
    		 -2.18

    PEG Ratio

    n/a
    		 0.07
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for REGENXBIO.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.32.

    Current Ratio

    n/a
    		 2.69

    Quick Ratio

    n/a
    		 2.69

    Debt / Equity

    n/a
    		 0.32

    Debt / EBITDA

    n/a
    		 -0.41

    Debt / FCF

    n/a
    		 -0.47

    Interest Coverage

    n/a
    		 -18.43

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $236,056.66

    Profits Per Employee

    n/a
    		 $-643,348.44

    Employee Count

    n/a
    		 353

    Asset Turnover

    n/a
    		 0.18

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -21.48% in the last 52 weeks. The beta is 1.09, so REGENXBIO's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.09

    52-Week Price Change

    n/a
    		 -21.48%

    50-Day Moving Average

    n/a
    		 8.45

    200-Day Moving Average

    n/a
    		 8.8

    Relative Strength Index (RSI)

    n/a
    		 49.44

    Average Volume (20 Days)

    n/a
    		 1,170,993

    Income Statement

    In the last 12 months, REGENXBIO had revenue of 83.33M and earned -227.1M in profits. Earnings per share was -4.59.

    Revenue

    n/a
    		 83.33M

    Gross Profit

    n/a
    		 49.76M

    Operating Income

    n/a
    		 -233.35M

    Net Income

    n/a
    		 -227.1M

    EBITDA

    n/a
    		 -198.23M

    EBIT

    n/a
    		 -214.44M

    Earnings Per Share (EPS)

    n/a
    		 -4.59
    Full Income Statement

    Balance Sheet

    The company has 57.53M in cash and 82.03M in debt, giving a net cash position of -24.51M.

    Cash & Cash Equivalents

    n/a
    		 57.53M

    Total Debt

    n/a
    		 82.03M

    Net Cash

    n/a
    		 -24.51M

    Retained Earnings

    n/a
    		 -932.15M

    Total Assets

    n/a
    		 490.93M

    Working Capital

    n/a
    		 206.51M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -173.13M and capital expenditures -2.44M, giving a free cash flow of -175.56M.

    Operating Cash Flow

    n/a
    		 -173.13M

    Capital Expenditures

    n/a
    		 -2.44M

    Free Cash Flow

    n/a
    		 -175.56M

    FCF Per Share

    n/a
    		 -3.55
    Full Cash Flow Statement

    Margins

    Gross margin is 59.72%, with operating and profit margins of -280.03% and -272.54%.

    Gross Margin

    n/a
    		 59.72%

    Operating Margin

    n/a
    		 -280.03%

    Pretax Margin

    n/a
    		 -272.54%

    Profit Margin

    n/a
    		 -272.54%

    EBITDA Margin

    n/a
    		 -237.89%

    EBIT Margin

    n/a
    		 -280.03%

    FCF Margin

    n/a
    		 -210.69%

    Dividends & Yields

    RGNX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RGNX is $30, which is 228.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $30

    Price Target Difference

    n/a
    		 228.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -1.52

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist